Talazoparib CAS NO 1207456-01-6 Inquire about Talazoparib

Tecoland supplies Talazoparib bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Talazoparib is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.
What is talazoparib?Talazoparib

Talazoparib is used to treat HER2-negative breast cancer that has spread to other parts of the body.

Talazoparib is used only if your cancer has a specific genetic marker (an abnormal “BRCA” gene). Your doctor will test you for this gene.

Talazoparib may also be used for purposes not listed in this medication guide.

Important Information

Using talazoparib may increase your risk of developing bone marrow problems or leukemia.

Talazoparib can lower your blood cell counts, and you may get an infection or bleed more easily. Call your doctor if you have unusual bruising or bleeding, blood in your urine or stools, weight loss, fever, weakness, tiredness, or trouble breathing.

You will need weekly or monthly blood tests, and your cancer treatments may be delayed based on the results.

Before taking this medicine

Tell your doctor if you have ever had:

  • kidney disease.

Using talazoparib may increase your risk of developing bone marrow problems or leukemia. Ask your doctor about this risk.

You may need to have a negative pregnancy test before starting this treatment.

Talazoparib can harm an unborn baby or cause a miscarriage if the mother or the father is using talazoparib.

  • If you are a woman,do not use talazoparib if you are pregnant. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 7 months after your last dose.
  • If you are a man,use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 4 months after your last dose.
  • Tell your doctor right away if a pregnancy occurs while either the mother or the father is using talazoparib.

This medicine may affect fertility (ability to have children) in men. However, it is important to use birth control to prevent pregnancy because talazoparib can harm an unborn baby.

Do not breastfeed while using this medicine, and for at least 1 month after your last dose.

Talazoparib is not approved for use by anyone younger than 18 years old.

How should I take talazoparib?

Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose. Use the medicine exactly as directed.

You may take talazoparib with or without food.

Swallow the capsule whole and do not dissolve or open it.

If you vomit shortly after taking talazoparib, do not take another dose. Wait until your next scheduled dose time to take the medicine again.

Talazoparib is usually given until your body no longer responds to the medication.

Talazoparib can lower your blood cell counts, and you may get an infection or bleed more easily. You will need weekly or monthly blood tests, and your cancer treatments may be delayed based on the results.

Store at room temperature away from moisture and heat.

You should not stop using talazoparib without first asking your doctor.

What happens if I miss a dose?

Skip the missed dose and use your next dose at the regular time. Do not use two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking talazoparib?

Follow your doctor’s instructions about any restrictions on food, beverages, or activity.

Talazoparib side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • blood in your urine or stools;
  • easy bruising, unusual bleeding, purple or red spots under your skin;
  • weight loss;
  • low red blood cells (anemia)–pale skin, weakness, feeling tired or short of breath, cold hands and feet; or
  • low white blood cell counts–fever, mouth sores, skin sores, sore throat, cough, trouble breathing.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects may include:

  • low blood cell counts;
  • nausea, vomiting, diarrhea, loss if appetite;
  • hair loss;
  • headache; or
  • feeling weak or tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Talazoparib dosing information

Usual Adult Dose for Breast Cancer:

1 mg orally once a day until disease progression or unacceptable toxicity

-Select patients based on the presence of germline BRCA mutations as determined by an FDA-approved test.

Use: For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer

What other drugs will affect talazoparib?

Tell your doctor about all your other medicines, especially:

  • amiodarone;
  • carvedilol;
  • clarithromycin;
  • itraconazole; or

Other drugs may affect talazoparib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.


Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.

External Link:

Talazoparib. (n.d.). Drugs.Com. https://www.drugs.com/mtm/talazoparib.html